Loubaton Bertrand
20 years experience in Drugs & Medical Technologies in both R&D and marketing.His current responsibility in GE Healthcare involves collaboration between academia and industry, for new technologies & biomarkers development.
Previously he was Business Development Director at SMV, Director of Operations/France Executive Director and Co-founder of the First European clinical sites network (SMO), Marketing/Sales Director of IBAH (Clinical Research Organization; & Product Manager at 3M Pharma & Roussel-Uclaf group
"Nanotechnologies in Medicine - Challenges and new concepts - The European Technology Platform on Nanomedicine"
Expectations are very high that nanotechnology can boost the development of novel drugs or new treatments. New models of cooperation between academic, industry and clinical stakeholders have to be sought and implemented. Industry is radically changing and open innovation concepts are more and more introduced by industrial players.
The ETP Nanomedicine, a network of industrial, academic and public stakeholders is accompanying this process, is supporting translation and open innovation.